Stocktoria
IONIS PHARMACEUTICALS INC IONS
IONIS PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $943.7M | $705.1M | $787.6M | $587.4M | $810.5M | $729.3M | $1.1B | $599.7M | $514.2M | $372.8M |
| R&D expense | $915.6M | $901.5M | $899.6M | — | $638.2M | $531.0M | $461.5M | $411.9M | $372.5M | $340.4M |
| SG&A expense | $393.9M | $267.5M | $232.6M | $150.3M | $186.3M | $354.3M | $286.6M | $244.6M | $108.5M | $48.6M |
| Operating income | -$381.7M | -$475.1M | -$353.7M | -$410.2M | -$30.2M | -$172.1M | $365.9M | -$61.4M | $31.0M | -$20.2M |
| Interest expense | $17.3M | $17.0M | $12.7M | $8.1M | $9.3M | $9.5M | $12.4M | $44.8M | $44.8M | $38.8M |
| Income tax | $1.8M | -$6.2M | $32.3M | $11.7M | -$551,000 | $345.2M | $51.5M | -$291.1M | -$6.0M | $2.9M |
| Net income | -$381.4M | -$453.9M | -$366.3M | -$269.7M | -$28.6M | -$444.3M | $278.1M | $273.7M | $346,000 | -$60.4M |
| EPS (diluted) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 | $1.90 | $2.07 | $0.15 | $-0.50 |
| Operating cash flow | -$268.6M | -$500.9M | -$307.5M | -$274.4M | $30.8M | $35.9M | $345.6M | $602.9M | $174.1M | -$112.1M |
| Free cash flow | -$320.0M | -$546.2M | -$331.3M | -$290.1M | $18.8M | $772,000 | $314.7M | $589.3M | $139.4M | -$119.2M |
| Cash & equivalents | $372.3M | $242.1M | $399.3M | $276.5M | $869.2M | $397.7M | $683.3M | $278.8M | $129.6M | $84.7M |
| Inventory | $10.0M | $12.5M | $7.4M | $22.0M | $24.8M | $22.0M | $18.2M | $8.6M | $10.0M | — |
| Total assets | $3.5B | $3.0B | $3.0B | $2.5B | $2.6B | $2.4B | $3.2B | $2.7B | $1.3B | $912.5M |
| Total liabilities | $3.0B | $2.4B | $2.6B | $2.0B | $1.8B | $1.6B | $1.5B | $1.5B | $957.5M | $812.9M |
| Shareholders' equity | $489.1M | $588.4M | $386.7M | $572.9M | $771.7M | $743.3M | $1.6B | $1.1B | $365.3M | $99.6M |
Growth · year-over-year · Revenue CAGR 10.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +33.8% | -10.5% | +34.1% | -27.5% | +11.1% | -35.0% | +87.2% | +16.6% | +37.9% | +31.4% |
| Net income growth | — | — | — | — | — | -259.7% | +1.6% | +79015.9% | — | — |
| EPS growth | — | — | — | — | — | -267.4% | -8.2% | +1280.0% | — | — |
| Free cash flow growth | — | — | — | -1639.4% | +2340.9% | -99.8% | -46.6% | +322.8% | — | -987.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.